Seegene USA's Allplex™ HSV-1&2/VZV/MPXV Assay receives Emergency Use Authorization from the U.S. Food and Drug Administration (FDA)The multiplex real-time PCR assay is designed to simultaneously detect and differentiate herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus (VZV) and monkeypox virus (MPXV clades I/II and clade II), which are associated with clinically overlapping vesicular, pustular, and ulcerative lesions in a single testIt is the first multiplex PCR test designed to support differential diagnosis of viral causes of ulcerative skin lesions in the U.S. market.
Virus-only testing may miss pneumonia-associated bacterial co-detections in 78% of virus-positive cases, while bacteria-only testing may miss viral co-detections in 88% of cases positive for pneumonia-associated bacterial pathogensGlobal Million Clinical Study (GMCS) to build clinical evidence supporting comprehensive syndromic PCR testing as a new global testing standard
Virus-only testing may miss pneumonia-associated bacterial co-detections in 78% of virus-positive cases, while bacteria-only testing may miss viral co-detections in 88% of cases positive for pneumonia-associated bacterial pathogensGlobal Million Clinical Study (GMCS) to build clinical evidence supporting comprehensive syndromic PCR testing as a new global testing standard
Seegene is launching the Global Million Clinical Study at the scale of one million test cases to shape disease-specific testing standards.The study is designed to evaluate the clinical utility of syndromic PCR testing approaches and build real-world scientific evidence to support better-informed clinical decision-making.The company is recognized as one of TIME's "The World's Most Impactful Companies of 2026," highlighting its work to address high-priority global challenges as part of its core business, as well as its global economic reach and positive impact on the world.
Seegene is launching the Global Million Clinical Study at the scale of one million test cases to shape disease-specific testing standards.The study is designed to evaluate the clinical utility of syndromic PCR testing approaches and build real-world scientific evidence to support better-informed clinical decision-making.The company is recognized as one of TIME's "The World's Most Impactful Companies of 2026," highlighting its work to address high-priority global challenges as part of its core business, as well as its global economic reach and positive impact on the world.
Seegene is launching the Global Million Clinical Study at the scale of one million test cases to shape disease-specific testing standards.The study is designed to evaluate the clinical utility of syndromic PCR testing approaches and build real-world scientific evidence to support better-informed clinical decision-making.The company is recognized as one of TIME's "The World's Most Impactful Companies of 2026," highlighting its work to address high-priority global challenges as part of its core business, as well as its global economic reach and positive impact on the world.
